Disease · MONDO_0004975

Alzheimer disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Alzheimer disease. Diseases, record MONDO_0004975. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004975

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Alzheimer disease; Open Targets
Open Targets ID: MONDO_0004975; Open Targets
Other names: AD, AD - Alzheimer's disease, ALZHEIMER DIS, ALZHEIMERS DIS, Alzheimer Dementia, Presenile, Alzheimer Type Dementia, Alzheimer dementia, Alzheimer's, Alzheimer's dementia, Alzheimer's disease, Alzheimer's disease (disorder), Alzheimer's disease, NOS, Alzheimers, Alzheimers Dementia, Alzheimers disease, DAT - Dementia Alzheimer's type, Dementia in Alzheimer's disease, Dementia in Alzheimer's disease (disorder), Dementia in Alzheimer's disease, unspecified (disorder), Dementia of the Alzheimer's type, Dementia, Alzheimer Type, Dementia, Presenile, Dementia, Presenile Alzheimer, Disease, Alzheimer, Disease, Alzheimer's, Presenile Alzheimer Dementia, [X]Dementia in Alzheimer's disease, [X]Dementia in Alzheimer's disease (disorder), presenile and senile dementia, sporadic Alzheimer's disease; Open Targets
Disease Ontology: DOID:10652; Disease Ontology
MeSH: D000544; MeSH
NCI Thesaurus: C2866; NCI Thesaurus
Orphanet: ORPHA:238616; Orphanet
Highest stage of its drugs: Approval, for 24 of its 441 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs441

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DONEPEZIL	CHEMBL502	Small molecule	Approval	PMDA and TTD	74	72	72	Drugs and targets
RIVASTIGMINE	CHEMBL636	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	53	38	38	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Approval	EMA Human Drugs and TTD	48	38	38	Drugs and targets
GALANTAMINE	CHEMBL659	Small molecule	Approval	TTD	25	24	24	Drugs and targets
DONEPEZIL HYDROCHLORIDE	CHEMBL1678	Small molecule	Approval	DailyMed	64	23	23	Drugs and targets
LECANEMAB	CHEMBL3833321	Antibody	Approval	EMA Human Drugs, FDA, PMDA and TTD	24	19	19	Drugs and targets
DONANEMAB	CHEMBL4297245	Antibody	Approval	EMA Human Drugs, FDA and PMDA	20	14	14	Drugs and targets
GALANTAMINE HYDROBROMIDE	CHEMBL1555	Small molecule	Approval	DailyMed and PMDA	14	11	11	Drugs and targets
ADUCANUMAB	CHEMBL3039540	Antibody	Approval	FDA and TTD	12	9	9	Drugs and targets
GV-971	CHEMBL4650397		Approval	TTD	10	8	0	Drugs and targets

1 to 10 of 441

See all 441 drugs

Targets314

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
APP	Amyloid-beta precursor protein	13	Amyloid-beta A4 protein binding agent; Amyloid-beta A4 protein disrupting agent; Amyloid-beta A4 protein inhibitor; Amyloid-beta A4 protein stabiliser; Amyloid-beta A4 protein vaccine antigen	Approval	https://conductscience.org/library/genes/351	Drugs and targets
DRD2	D(2) dopamine receptor	10	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	10	Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
ACHE	Acetylcholinesterase	9	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Approval	https://conductscience.org/library/genes/43	Drugs and targets
CHRNA7	Neuronal acetylcholine receptor subunit alpha-7	8	Neuronal acetylcholine receptor protein alpha-7 subunit agonist; Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist; Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/1139	Drugs and targets
PTGS2	Cyclooxygenase	8	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	6	Muscarinic acetylcholine receptor M1 agonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/1128	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel inverse agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel inverse agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB3	GABA-A receptor; agonist GABA site	6	GABA receptor beta-3 subunit positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel inverse agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 314

See all 314 targets

Trials774

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 31 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02245737	An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease	Phase 2/3	2,218	2019-08-06	Alzheimer´s Disease	LANABECESTAT	Its record names the disease	ClinicalTrials.gov
NCT02956486	A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease	Phase 3	2,212	2021-02-03	Alzheimer's Disease	ELENBECESTAT	Its record names the disease	ClinicalTrials.gov
NCT01739348	An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)	Phase 2/3	2,211	2018-05-16	Alzheimer's Disease	VERUBECESTAT	Its record names the disease	ClinicalTrials.gov
NCT01900665	Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo	Phase 3	2,129	2018-03-14	Alzheimer's Disease	SOLANEZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00679627	A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease	Phase 3	2,051	2013-09-02	Alzheimer's Disease	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT01734395	A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease		1,882	2013-08-05	Alzheimer's Disease	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT04437511	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	Phase 3	1,736	2024-05-20	Alzheimer Disease	DONANEMAB	Its record names the disease	ClinicalTrials.gov
NCT02783573	A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia	Phase 3	1,722	2019-08-06	Alzheimer's Disease	LANABECESTAT	Its record names the disease	ClinicalTrials.gov
NCT04241068	A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205	Phase 3	1,696	2025-02-21	Alzheimer's Disease	ADUCANUMAB	Its record names the disease	ClinicalTrials.gov
NCT02477800	221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease	Phase 3	1,653	2021-09-02	Alzheimer's Disease	ADUCANUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 774

See all 774 trials

Comparisons in its trials245

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Galantamine vs Placebo: serious adverse events	129 of 1,024	123 of 1,021	2,045	NCT00679627	Trial comparisons
Donanemab vs Placebo: deaths from any cause	16 of 853	10 of 874	1,727	NCT04437511	Trial comparisons
Donanemab vs Placebo: serious adverse events	148 of 853	138 of 874	1,727	NCT04437511	Trial comparisons
Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies	693 of 793	48 of 821	1,614	NCT04437511	Trial comparisons
Idalopirdine 60 mg vs Idalopirdine 60 mg + Memantine: deaths from any cause	11 of 1,462	0 of 101	1,563	NCT02079246	Trial comparisons
Idalopirdine 60 mg vs Idalopirdine 60 mg + Memantine: serious adverse events	91 of 1,462	2 of 101	1,563	NCT02079246	Trial comparisons
Solanezumab vs Placebo: serious adverse events	299 of 734	308 of 723	1,457	NCT01127633	Trial comparisons
Donepezil SR 23 mg vs Donepezil IR 10 mg: serious adverse events	80 of 963	45 of 471	1,434	NCT00478205	Trial comparisons
Bapineuzumab vs Placebo: serious adverse events	137 of 654	77 of 439	1,093	NCT00676143	Trial comparisons
Aducanumab vs Placebo: deaths from any cause	3 of 681	0 of 343	1,024	NCT05310071	Trial comparisons

1 to 10 of 245

See all 245 comparisons in its trials

Papers from its trials440

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41574278	RESULT	1	PubMed
41313764	RESULT	1	PubMed
36581878	RESULT	1	PubMed
36281668	RESULT	1	PubMed
36168659	RESULT	1	PubMed
35908254	RESULT	1	PubMed
35662833	RESULT	1	PubMed
34570177	RESULT	2	PubMed
34145880	RESULT	1	PubMed
33778150	RESULT	1	PubMed

1 to 10 of 440

See all 440 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004975

GET https://conductscience.org/api/diseases/v1/MONDO_0004975/drugs?page=2

API reference For AI assistants